Nuvation Bio Q2 2026 revenue $31.7M, IBTROZI net product revenue $23.2M; net loss $62.8M

Nuvation Bio Inc.

2026-Q2 EPS reported -$0.17 revenue$114,915,000

Total revenue $31.7M, including $23.2M net product revenue from IBTROZI (ROS1 TKI) and $8.5M collaboration/license revenue.
Net loss $62.8M ($0.18/share) vs $59.0M ($0.17/share) in Q2 2025; R&D spend $30.7M, SG&A $42.6M.
Cash, equivalents, and marketable securities $661.0M as of June 30, 2026; additional $36.5M from July convertible notes overallotment.
IBTROZI most prescribed ROS1 TKI in 2026; ~85% of ~160 new patient starts were TKI-naïve (30% QoQ growth).
Safusidenib Phase 2 shows 51.9% ORR, median PFS not reached at 38.8 months; pivotal Phase 3 and Phase 2 studies initiated.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.